SPARC and neoplasm: When patients with stage II and III CRC were divided into those with a good outcome (no disease recurrence within 5 years of diagnosis) and a poor outcome (disease recurrence within 5 years of diagnosis or death from disease), patients with a good disease outcome in both stage II and III had higher SPARC expression in the primary tumour, but these findings were not significantly different (Figure 2C).